Sandeep Chaudhary, MD
Endocrinology · Laguna Hills, CANPI 1417055872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Lilly USA, LLC at 32.1% of the total. Reporting peaked in 2019 at $634 and has fallen 66.3% since, to $214 in 2025.
Across 156 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$765
- Sanofi-aventis U.S. LLC$303
- Novo Nordisk$141
- Merck$115
- IBSA Pharma Inc.$106
- Abbott$103
- plus $848 from 17 others
What the payments were for
- Food & beverage$2,372100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 59 | $765 |
| Sanofi-aventis U.S. LLC | 18 | $303 |
| Novo Nordisk | 9 | $141 |
| Merck | 7 | $115 |
| IBSA Pharma Inc. | 6 | $106 |
| Abbott | 5 | $103 |
| Radius Health, Inc. | 4 | $82 |
| AstraZeneca | 6 | $81 |
| Medtronic | 5 | $79 |
| Mannkind Corporation | 4 | $71 |
| Shire North American Group Inc | 4 | $66 |
| Vistapharm, Inc. | 4 | $64 |
| Insulet Corporation | 4 | $62 |
| Recordati_rare_diseases_inc. | 4 | $61 |
| Acella Pharmaceuticals, LLC | 4 | $58 |
| Boehringer Ingelheim | 3 | $49 |
| Johnson & Johnson | 2 | $34 |
| AbbVie | 2 | $33 |
| Cequr Corporation | 1 | $31 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$2,380 in reported general payments places this provider in the 80th percentile of 58 endocrinology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 39 | $57,371 |
| RybelsusSemaglutide | 30 | $34,201 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $22,307 |
| JardianceEmpagliflozin | 13 | $21,174 |
| JanuviaSitagliptin Phosphate | 16 | $12,755 |
| SynthroidLevothyroxine Sodium | 108 | $10,438 |
| Liothyronine Sodium | 119 | $4,247 |
| TirosintLevothyroxine Sodium | 11 | $2,741 |
| ProgesteroneProgesterone, Micronized | 33 | $1,748 |
| Levothyroxine Sodium | 148 | $1,745 |
| Armour ThyroidThyroid,pork | 13 | $1,132 |
| DottiEstradiol | 20 | $912 |
| LevoxylLevothyroxine Sodium | 22 | $858 |
| Hydrocortisone | 36 | $740 |
| UnithroidLevothyroxine Sodium | 12 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $765 | $57,37139 claims |
| Novo NordiskRybelsus | $141 | $34,20130 claims |
| Boehringer IngelheimJardiance | $49 | $21,17413 claims |
| MerckJanuvia | $115 | $12,75516 claims |
| AbbVieSynthroid, Armour Thyroid | $33 | $11,570121 claims |
| IBSA Pharma Inc.Tirosint | $106 | $2,74111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 58 endocrinology providers in California.
Other endocrinology in Laguna Hills
- Minh MachBurbank$559K
- Joseph HawkinsFresno$477K
- Michael BushBeverly Hills$380K
- Shawna WeislerBurbank$45K
- Ashiq PatelLancaster$32K
- Paul AzerBeverly Hills$25K
- Michael TranAnaheim$16K
- Samuel MayedaOrange$11K
- Daniel KaplanSan Leandro$8K
- Amy van BuiMission Viejo$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.